MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
33.26
-2.42
-6.78%
After Hours: 33.29 +0.03 +0.09% 18:25 05/13 EDT
OPEN
34.73
PREV CLOSE
35.68
HIGH
34.84
LOW
33.21
VOLUME
6.48M
TURNOVER
--
52 WEEK HIGH
39.54
52 WEEK LOW
21.62
MARKET CAP
6.32B
P/E (TTM)
-9.4202
1D
5D
1M
3M
1Y
5Y
1D
BridgeBio announces first participant dosed with acoramidis in ACT-EARLY
TipRanks · 11h ago
BridgeBio Pharma Has Dosed The First Asymptomatic Participant With A Known Pathogenic Transthyretin Variant, Which May Lead To Transthyretin Amyloid Disease In ACT-EARLY Study With Acoramidis
Benzinga · 11h ago
Invesco Discovery Fund Q1 2025 Commentary
Seeking Alpha · 15h ago
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
Barchart · 16h ago
BridgeBio To Present ATTRibute-CM Study Findings At Heart Failure 2025 Congress
Benzinga · 1d ago
Weekly Report: what happened at BBIO last week (0505-0509)?
Weekly Report · 1d ago
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
Barchart · 1d ago
J.P. Morgan Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
TipRanks · 6d ago
More
About BBIO
More
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Recently
Symbol
Price
%Change

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.